v3.25.2
Segments - Schedule of Segment Reporting (Details) - USD ($)
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Schedule of Segment Reporting [Line Items]      
Revenues $ 248,536 $ 110,990  
Gross margin 178,655 95,124  
Depreciation and amortization 6,491 9,056  
Selling, general and administrative 525,020 404,375  
Research and development 170,329 151,049  
Total Operating expenses 701,840 564,480  
Other expenses      
Interest expense (111,093) (107,487)  
Fair value adjustment 30,511 (17,996)  
Other income (loss), net 1,035 1,707  
Other expenses (79,547) (123,776)  
Net income (602,732) (593,132)  
Assets of segment 1,625,819 1,378,768 $ 1,381,561
Biotechnology [Member]      
Schedule of Segment Reporting [Line Items]      
Revenues  
Gross margin  
Depreciation and amortization 6,491 9,056  
Selling, general and administrative 484,739 363,801  
Research and development 144,776 124,600  
Total Operating expenses 636,006 497,457  
Other expenses      
Interest expense (111,093) (107,487)  
Fair value adjustment 30,511 (17,996)  
Other income (loss), net 1,035 1,707  
Other expenses (79,547) (123,776)  
Net income (715,553) (621,233)  
Assets of segment 1,625,478 1,375,638  
Pharmaceutical [Member]      
Schedule of Segment Reporting [Line Items]      
Revenues 248,536 110,990  
Gross margin 178,655 95,124  
Depreciation and amortization  
Selling, general and administrative 40,281 40,574  
Research and development 25,553 26,449  
Total Operating expenses 65,834 67,023  
Other expenses      
Interest expense  
Fair value adjustment  
Other income (loss), net  
Other expenses  
Net income 112,821 (28,101)  
Assets of segment $ 341 $ 3,130